Coronary artery disease and peripheral artery disease are global public health and socioeconomic issues that affect millions of lives each year. Bioabsorbable stents, which provide transient support to the vessel and degrade overtime, are viable alternatives to permanent drug-eluting and bare metal stent implants. In the report, bioabsorbable stents are defined as fully biodegradable stents that completely disappear over time. The emerging Bioabsorbable Stent (BAS) market is steadily growing in the major markets in Europe (France, Germany, Italy, Spain and the UK), dominated by Abbott Vascular and Kyoto Medical Planning, with new entrants including Biotronik, REVA Medical and Elixir Medical Corporation. In the US, bioabsorbable stents have not received regulatory approval and are not available for sale. By the end of our forecast period, the competitive landscape will experience significant change due to the launch of BAS products in the US, the expansion of approved indications to include patients with more complex forms of coronary and peripheral artery disease and the entry of new companies such as OrbusNeich and Arterial Remodelling Technologies by 2018.
This report is built using data and information sourced from secondary sources and primary research interviews with leading Interventional Cardiologists, Cardiovascular Surgeons and Interventional Radiologists with in-house analysis conducted by GlobalData’s team of industry experts.
Questions Answered in this Report
Drug-Eluting and Bare Metal Stents have been on the market for many years; however, unmet needs still exist in terms of implantation, safety and efficacy. How will Bioabsorbable Stents currently in the market and in development fulfil the unmet needs of the stent market?
Bioabsorbable Stent technology is in the early stages of development. What is the current perception and adoption of this innovative stent platform in the major markets?
Currently, only two Bioabsorbable Stents have received approval and are commercially available in Europe, the Middle East and parts of Asia and Latin America. As more BASs receive approval, how will new entrants impact the BAS medical device market?
BAS procedure volumes have been slowly increasing in the major European markets. What are the key factors and opportunities that will drive the BAS market in terms of future adoption rates leading to a mature market?
Regions Covered: US, France, Germany, Italy, Spain, and UK
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs, physicians, industry participants and distributors is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, procedure volumes, average selling prices, and market values over a 10 - year period (2009 – 2018). The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.
What Physicians Think
What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading Interventional Cardiologists and Interventional Radiologists from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
*Interactive excel forecast model only available to clients purchasing a site license or higher.